# Windows of Susceptibility to Air Pollution During and Surrounding Pregnancy in Relation to Longitudinal Maternal Measures of Adiposity and Lipid Profiles

Sandra India Aldana<sup>1</sup>; Danielle Demateis<sup>2</sup>; Damaskini Valvi<sup>1</sup>; Allan C. Just<sup>3</sup>; Iván Gutiérrez-Avila<sup>1</sup>; Guadalupe Estrada-Gutierrez<sup>4</sup>; Martha María Téllez Rojo<sup>5</sup>; Robert O. Wright<sup>1</sup>; Andrea A. Baccarelli<sup>6</sup>; Haotian Wu<sup>7</sup>; Kayleigh P. Keller<sup>2</sup>; Ander Wilson<sup>2</sup>; Elena Colicino<sup>1</sup>

\*Corresponding author:

Sandra India Aldana, MPH, MPhil, PhD
Postdoctoral Fellow
Department of Environmental Medicine and Climate Science
Icahn School of Medicine at Mount Sinai
17 E 102 St, Floor 3
New York, NY 10029
Email: sandra.india-aldana@mssm.edu

<sup>&</sup>lt;sup>1</sup>Department of Environmental Medicine and Climate Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>&</sup>lt;sup>2</sup>Department of Statistics, Colorado State University, Fort Collins, CO, USA

<sup>&</sup>lt;sup>3</sup>Brown University, Providence, RI, USA

<sup>&</sup>lt;sup>4</sup>Department of Immunobiochemistry, Research Division, National Institute of Perinatology, Mexico City, Mexico.

<sup>&</sup>lt;sup>5</sup>Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.

<sup>&</sup>lt;sup>6</sup>Harvard T.H. Chan School of Public Health, Boston, MA, USA.

<sup>&</sup>lt;sup>7</sup>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA

# **Abstract**

Pregnancy is a critical window for long-term metabolic programming of fetal effects stemming from airborne particulate matter ≤2.5µm (PM<sub>2.5</sub>) exposure. Yet, little is known about long-term metabolic effects of PM<sub>2.5</sub> exposure during and surrounding pregnancy in mothers. We assessed potential critical windows of PM<sub>2.5</sub> exposure during and surrounding pregnancy with maternal adiposity and lipid measures later in life. We included 517 pregnant women from the PROGRESS cohort with adiposity [body mass index (BMI), waist circumference (WC), % body fat] and lipids [total cholesterol, high-density-lipoprotein (HDL), low-density-lipoprotein (LDL)] measured repeatedly at 4, 6 and 8 years post-delivery. Monthly average PM<sub>2.5</sub> exposure was estimated at each participant's address using a validated spatiotemporal model. We employed distributed lag interaction models (DLIMs) adjusting for socio-demographics and clinical covariates. We found that a 1 µg/m<sup>3</sup> increase in PM<sub>2.5</sub> exposure throughout mid-/late-pregnancy was associated with higher WC at 6-years post-delivery, peaking at 6 months of gestation: 0.04 cm (95%CI: 0.01, 0.06). We also identified critical windows of PM<sub>2.5</sub> exposure during and surrounding pregnancy associated with higher LDL and lower HDL both measured at 4 years post-delivery with peaks at pre-conception for LDL [0.17 mg/dL (95%CI: 0.00, 0.34)] and at the 11th month after conception for HDL [-0.07 mg/dL (95%CI: -0.11, -0.02)]. Stratified analyses by fetal sex indicated stronger associations with adiposity measures in mothers carrying a male, whereas stronger associations were observed with lipids in mothers carrying a female fetus. Stratified analyses also indicated potential stronger deleterious lagged effects in women with folic acid intake lower than 600mcg/day during pregnancy.

#### **Keywords**

Critical windows; pregnancy; maternal health; air pollution; adiposity; lipids

#### 1. Introduction

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Obesity and dyslipidemia are key cardiometabolic risk factors and conditions that predispose individuals to increased risk of stroke, disability, and mortality. 1,2 These conditions have increased in North America at an alarming rate throughout the past decades<sup>3-10</sup> and are particularly more prevalent among Hispanics. 11,12 In Mexican adults, dyslipidemias are the most prevalent risk factor for cardiovascular diseases, <sup>13</sup> including hypoalphalipoproteinemia, also known as low high-density lipoprotein (HDL), and high low-density lipoprotein (LDL), with an estimated prevalence of ~55%. Excess adiposity and low HDL predispose individuals to increased metabolic syndrome, a condition on the rise in Mexico, where it is estimated to affect 56% of the adult population.<sup>6</sup> Importantly, metabolic disease-related morbidities and mortality affect women more than men in Mexico. 10 According to the 2018-2019 ENSANUT National Health Nutrition Survey there are substantial higher rates of generalized and abdominal obesity in Mexican adult women compared to men, 14 with a peak prevalence in women of 40.2% for generalized obesity and 88% for abdominal obesity. Airborne particulate matter with an aerodynamic diameter of 2.5 microns or smaller (PM<sub>2.5</sub>) is a ubiquitous exposure in urban, industrial, and rural environments. <sup>15,16</sup> PM<sub>2,5</sub> exposure can have endocrine-disrupting effects 17-20 and is considered an emerging risk factor for obesity and adverse metabolic outcomes. 21-23 Experimental studies in animals and epidemiological research in humans have demonstrated that PM<sub>2.5</sub> exposure may promote weight gain and adipose tissue expansion, and alter lipid metabolism.<sup>24-29</sup> Mechanisms by which PM<sub>2.5</sub> could influence metabolic diseases include hormonal alteration, increased inflammation, oxidative stress, and reactive oxygen species-induced endothelial dysfunction.<sup>30-34</sup> Furthermore, PM<sub>2.5</sub> exposure during pregnancy has been suggested to be a critical exposure window for a wide variety of health-related outcomes in both birthing-mothers and children. 35-40 However, most of the

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

literature examining critical PM<sub>2.5</sub> exposure windows during pregnancy has primarily focused on children's health, largely missing potential long-term effects in mothers. 41 Pregnancy constitutes a major period of physiological changes<sup>42</sup> including pro-inflammatory processes<sup>43-45</sup> and weight gain. 46,47 The numerous physiological changes occurring during pregnancy may lead to potential lingering chronic diseases and metabolic effects. 48-52 Research on pregnancy as a window of susceptibility to environmental exposures in mothers is scarce<sup>41</sup> and overlook a potential period in which metabolic conditions may worsen or can effectively be prevented or treated. To date, no study has evaluated how PM<sub>2.5</sub> exposure during and surrounding gestation may affect maternal obesity and dyslipidemia in the years following delivery. Therefore, we assessed potential critical windows of PM<sub>2.5</sub> exposure during and surrounding pregnancy with later changes in markers for anthropometry and lipids in the years following delivery in women from the Mexican Programming Research in Obesity, Growth, Environment and Social Stressors (PROGRESS) study. To achieve this, we employ the novel distributed lag models with interaction to identify critical windows of PM<sub>2.5</sub> exposure for maternal health endpoints repeatedly measured over post-delivery follow-up visits.<sup>53</sup> Furthermore, given that maternal metabolic health and associated mechanisms are considered sex-dimorphic<sup>54</sup> and that folic acid (FA) may attenuate adverse health effects from air pollutants, <sup>55</sup> we also hypothesized potential effect modification by fetal sex and FA. 2. Material and Methods 2.1 Study Population The PROGRESS study enrolled 948 mother-children pairs between 2007-2011 that were followed for over a decade. 56 Healthy pregnant women, affiliated with the Mexican Social Security Institute, were recruited during the 2<sup>nd</sup> trimester of pregnancy (12-20 gestational

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

weeks). Any pregnant woman, ≥18 years old and living in Mexico City, with no intention of changing address location for at least three years, were eligible for enrollment. Medical exclusion criteria included history of infertility, heart or renal diseases, diabetes, psychosis or use of anti-epilepsy drugs, use of steroids, consumption of one or more alcoholic drinks per day, or drug addiction. All women enrolled in the study agreed to sign a consent form in Spanish. This study was approved by the Institutional Review Boards of the participating institutions: the Icahn School of Medicine at Mount Sinai and the "Instituto Nacional de Salud Pública" in Mexico. 2.2 Ambient PM<sub>2.5</sub> Exposure at Participants' Addresses Daily PM<sub>2.5</sub> predictions with a 1×1-km spatial resolution came from our machine-learning models developed for the Mexico City Metropolitan Area. Our models employed extreme gradient boosting (XGBoost) and inverse-distance weighting (IDW), incorporating satellite-based aerosol optical depth data from NASA's Terra and Aqua satellites, meteorological information, and landuse variables (**Methods S1**).<sup>57</sup> To limit the daily exposure variability and facilitate the interpretation of long-term maternal health effects from PM<sub>2.5</sub>, we averaged the daily PM<sub>2.5</sub> exposures into monthly ambient PM<sub>2.5</sub> exposure concentrations. We then focused on exposure surrounding pregnancy: pre-conception (approximately one and two months prior to the last menstrual period, LMP), during pregnancy (months 0-9 after LMP), and up to one year after childbirth (months 10-22 after LMP). We examine exposure time up to one year beyond birth as we hypothesize that lingering immediate effects from pregnancy or giving birth could make women more susceptible to environmental exposures. 2.3 Outcomes Repeated anthropometric and lipid measures were collected at three follow-up visits 4, 6 and 8 years post-delivery (corresponding to approximately 48, 72, and 96 months after childbirth).

Maternal anthropometric measures (weight, height, waist circumference, and body fat) were collected using standardized protocols. <sup>58-60</sup> We calculated body mass index (BMI) based on measured height (collected using a Seca 206 roller tape) and weight (collected by a trained physician). Medical staff measured body fat using InBody 270 or InBody 370 Body Composition Analyzers during each monitoring visit. WC was measured using a Seca tape (model 201) above the iliac crest. <sup>60</sup> Total cholesterol and high-density lipoprotein (HDL) cholesterol were measured by enzymatic photometric assays on a Response 910 automated analyzer (DiaSys Diagnostic Systems, Holzheim, Germany) in fasting plasma collected from participants at all post-delivery visits. Low-density lipoprotein (LDL) concentration was derived using the Friedewald equation. <sup>61</sup>

## 2.4 Additional Variables

Information on socio-demographic factors (age, marital status, socio-economic status) was self-reported at recruitment during the 2<sup>nd</sup> trimester of pregnancy. PROGRESS also collected lifestyle information at baseline and across follow-up visits: smoking, alcohol intake, medications (**Methods S2**), and parity. Self-reported information on multiple pregnancies throughout the follow-up was also monitored and documented in PROGRESS. Pregnancy start date was defined as the LMP, which was used as a proxy of the month of conception in this study. We used a standard physical assessment of gestational age (Capurro method)<sup>62</sup> when gestational age differed by more than three weeks from that assigned by the LMP (~4% of participants in the cohort). We estimated pre-pregnancy BMI in accordance to previous published methods using the height at recruitment and the LMP reported weight.<sup>58,63</sup> We assessed socio-economic status (SES) using the previously validated Mexican Association of Market and Public Opinion Research Agencies (Spanish acronym AMAI) index used in Mexico.<sup>64</sup> The AMAI index is an individual-level variable that considered a total of 13 factors including the education of the head of household, number of appliances in the household, car ownership, and so forth. The index

denotes six categories that were eventually collapsed into three levels of SES: lower (AMAI categories D and E), medium (AMAI categories C and D+), and higher (AMAI categories A, B, and C+). Our SES measures are relative as the cohort was predominantly low SES. Information on the sex of the child and self-reported FA supplementation intake during pregnancy (at trimesters 2 and 3) were also obtained.

#### 2. 5 Statistical Analyses

A total of n=806 women had monthly PM<sub>2.5</sub> exposure from two months prior to LMP through month 22 after LMP and no missing information on pre-pregnancy BMI, age, or meteorological season (**Figure S1**). Missing monthly exposure data during the time period of interest (accounting for <0.3% of the total monthly air pollution data in the cohort) were imputed using time series weighted moving averages.<sup>65</sup> Women with at least one cardiometabolic marker measured at any follow-up visit were eligible for inclusion resulting in an analytic sample size of n=517.

To evaluate the potential critical windows of PM<sub>2.5</sub> exposure over 25 months in later onset of cardiometabolic conditions (i.e. higher adiposity and cholesterol levels) at the 4, 6, and 8-year post-delivery visits, we implemented distributed lag interaction models (DLIMs).<sup>53</sup> The DLIM estimates a linear exposure-time-response function that varies continuously by time after delivery and by outcome assessment time (**Methods S3**). We compared three possible models for how the exposure effect varies across outcome time using a bootstrap likelihood ratio test: no modification, linear modification (i.e. linear scaling of the linear exposure effect across outcome times), or complex non-linear modification across outcome times. In all models, we adjusted for a core set of covariates based on their associations with both the exposure and outcomes or based on their clinical relevance as previously identified (**Figure S2**): age at

parturition (continuous),<sup>66</sup> pre-pregnancy BMI (continuous),<sup>67</sup> socio-economic status (lower, medium, higher),<sup>68</sup> smoking during pregnancy (any passive or active smoking reported during pregnancy),<sup>69,70</sup> marital status (single, separated or divorced vs. married or living with a partner),<sup>71,72</sup> parity at baseline (1<sup>st</sup> pregnancy, 2<sup>nd</sup> pregnancy, and 3<sup>rd</sup> or more pregnancies at recruitment),<sup>73,74</sup> season (dry-cold/November to February, dry-warm/March and April, rainy/May to October),<sup>75,76</sup> medications to treat cardiometabolic diseases<sup>77</sup> (self-report of a drug treatment for abnormal levels of either glucose, triglycerides, high-density lipoprotein (HDL), or blood pressure vs. lack thereof), alcohol intake (yes/no),<sup>78</sup> follow-up visit (stage), and follow-up time in months squared to allow for a non-linear effect. Given that lifestyle variables such as alcohol intake, medications, and pregnancy history could change over time, we updated the models with information on lifestyle data at each follow-up stage (at 4, 6, and 8 years post-delivery) as time-varying covariates.

We performed sensitivity analyses by fitting DLIMs 1) without pre-pregnancy BMI as covariate, 2) controlling for time-varying 1-year average PM<sub>2.5</sub> exposure prior to visit, and 3) without time-varying pregnancy as covariate, generating plots that are smoothed to allow for comparison of sensitivity analyses to our main analyses. Additional analyses were also conducted stratifying by important factors during pregnancy based on prior clinical relevance and/or previous research in PROGRESS. Given the shifting sex-steroid hormone concentrations during pregnancy dependent on fetal sex<sup>79,80</sup> and the protective interaction effects of FA with air pollutant mixtures and metabolic health in PROGRESS women, <sup>81</sup> we conducted stratified analyses by 1) fetal sex (mothers carrying a male vs. a female fetus) and by 2) FA intake using the average recommended FA supplementation for pregnant women according to clinical guidelines (600 mcg/day). <sup>82</sup> All statistical analyses were conducted using R software (version 4.3.0) with package *dlim* (version 0.1.0).

#### 3. Results

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Women were exposed on average to a PM<sub>2.5</sub> concentration of 22.8 µg/m<sup>3</sup> (standard deviation (SD): 1.5; interquartile range (IQR): 2.21) across the 25-month span from 2 month preconception up to 1-year post-partum (Table 1; Figure S3). Women were slightly overweight prior to pregnancy (nearly ~60% were either overweight or obese) with a mean (SD) BMI of 26.5 (4.1) kg/m<sup>2</sup> and were on average (SD) 29 (5.6) years old at the time of parturition. The majority of women had low socio-economic status (53%), reported previous pregnancies at baseline prior to index pregnancy (61%), were married or lived with a partner at the time of recruitment (81%), and did not smoke nor were exposed to passive (2<sup>nd</sup>-hand) smoke during pregnancy (63%). Participants were followed for nearly a decade after parturition and attended up to three follow-up examination visits at approximately 4 years [mean (min, max): 57 months (48, 80)], 6 years [mean (min, max): 80 months (71, 115)], and 8 years post-delivery [mean (min, max): 115 months (97, 142)]. Using DLIMs, we found evidence of non-linear modification of the exposure-time-response function across outcome times for all outcomes using the bootstrap likelihood ratio test (rejected null of linear modification versus the alternative of non-linear modification). We estimated critical windows of exposure surrounding pregnancy during which PM<sub>2.5</sub> exposure was linked with several anthropometric measures and lipid levels (Tables S1-S6), although these associations were not identified as statistically significant for all cardiometabolic markers examined. Pregnancy PM<sub>2.5</sub> exposure was associated with changes in several metabolic health measures up to the 6-year post-delivery visit (**Figures 1-2**). A 1-μg/m<sup>3</sup> increase in PM<sub>2.5</sub> exposure throughout the 2<sup>nd</sup> and 3<sup>rd</sup> trimesters of pregnancy (gestational months: 4-8 after LMP) was associated with an increase in WC levels at the 6-year post-delivery visit (Figure 1). The peak effect was at 6 months of gestation which showed an increase of 0.04 cm in WC (95% CI: 0.01,

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

0.06) per µg/m<sup>3</sup> PM<sub>2.5</sub> (**Figure 1**: **Table S2**). A suggestive late pregnancy window of susceptibility to PM<sub>2.5</sub> exposure was identified in relation to WC levels at the 4-year post-delivery visit [gestational month 9 after LMP: β = 0.03 (95% CI: -0.01, 0.06)]. In addition, we identified alterations in BMI at the 8-year post-delivery visit in association with a peri-conception window of PM<sub>2.5</sub> exposure (during pre-conception and early-pregnancy period) (**Figure 1**: **Table S1**). These negative PM<sub>2.5</sub>-BMI associations were not sustained in the sensitivity (**Figure S4**) and in the female-stratified (Figure S8) analyses, and can be driven by the over-adjustment with prepregnancy BMI. There was no evidence of associations in relation to percent body fat. PM<sub>2.5</sub> exposure surrounding pregnancy was associated with a dysregulation of several lipid levels at the 4-year post-delivery visit, but not thereafter (Figure 2). We observed a susceptible PM<sub>2.5</sub> exposure window from the 2<sup>nd</sup> trimester of pregnancy and up to the early post-partum period (critical window between months 6 and 18 after LMP) on high-density lipoprotein (HDL) cholesterol 4 years post-delivery (**Table S5**). The peak effect at the 11<sup>th</sup> month after LMP was associated with a 0.07 mg/dL decrease in HDL (95% CI: -0.11, -0.02) per µg/m<sup>3</sup> increase in PM<sub>2.5</sub>. In addition, we observed associations between increased PM<sub>2.5</sub> exposure throughout preconception, pregnancy, and the post-partum period (2 months prior to and up to month 17 after LMP) and higher low-density lipoprotein (LDL) cholesterol at the 4-year post-delivery visit. The largest associations occurred during pre-conception (2 months prior to conception) which led to an increase of 0.17 mg/dL in LDL (95% CI: 0.00, 0.34) per PM<sub>2.5</sub> µg/m<sup>3</sup> (**Table S6**). While no critical windows of susceptibility to PM<sub>2.5</sub> were observed with respect to total cholesterol, the overall trend was positive in directionality between the pre-conception and pregnancy PM<sub>2.5</sub> exposure periods with cholesterol levels at the 4-year post-delivery visit that attenuated over time.

Compared to main results, sensitivity analyses that did not control for pre-pregnancy BMI showed consistent windows of susceptibility to PM<sub>2.5</sub> exposure across health outcomes and across follow-up visits (Figures S4-S5). Also, no notable differences were observed in sensitivity models that controlled for time-varying 1-year PM<sub>2.5</sub> exposures average prior to follow-up visits (Figures S6-S7), or without time-varying pregnancies as covariate (Figures S8-**S9**). Stratified analyses by fetal sex indicated stronger effects positive in directionality on anthropometric markers in pregnant mothers carrying a male fetus compared to mothers carrying a female fetus (Figures S10-S12), particularly for WC (Figure S11). On the other hand, stratified analyses by fetal sex showed more persistent effects from PM<sub>2.5</sub> exposures during pregnancy on lipids over time in pregnant mothers carrying a female fetus (Figures S13-**S15**). For instance, windows of susceptibility to PM<sub>2.5</sub> on higher levels of LDL were sustained throughout all follow-up visits in pregnant mothers carrying a female fetus whereas the associations disappeared over time in those carrying a male fetus (Figure S15). Interestingly, stratified analyses by FA intake showed more prominent deleterious effects in the low FA intake group as compared to the high FA intake group (Figures S16-S21). This is apparent for all anthropometric outcomes but particularly for WC and body fat where women with lower FA intake levels during pregnancy had lagged PM<sub>2.5</sub>-induced increased levels of adiposity as compared to women with higher FA intake levels (Figures S17-S18). Similarly, it is notable that windows of susceptibility to PM<sub>2.5</sub> on higher LDL and lower HDL cholesterol were stronger in women with lower FA intake levels than in their counterparts (Figures S20-S21).

#### 4. Discussion

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

This is the first study assessing long-term alterations of maternal adiposity and lipid measures stemming from PM<sub>2.5</sub> exposures occurring during and surrounding the time of pregnancy (peripregnancy). Several maternal biomarkers assessed at the 4- and 6-year post-delivery visits

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

showed potentially deleterious associations from PM<sub>2.5</sub> exposures during the period surrounding pregnancy. Long-term adverse associations induced by pregnancy PM<sub>2.5</sub> exposure were particularly observed for WC (at the 6 year post-delivery visit) and for lipids (at the 4 year postdelivery visit). Critical PM<sub>2.5</sub> exposure windows were identified during mid and late pregnancy for WC, whereas for lipid outcomes sensitive windows were prominent throughout all pregnancy and during the first post-partum months. Stratified analyses by fetal sex indicated potential stronger deleterious effects with anthropometric measures that were more prominent in mothers carrying a male fetus, whereas PM<sub>2.5</sub> associations with lipid biomarkers were stronger in mothers carrying a female fetus. Stratified analyses indicated also potential stronger deleterious effects in women with lower FA intake during pregnancy. In this study, we showed that PM<sub>2.5</sub> exposures during and surrounding pregnancy could exacerbate potential physiological changes occurring during gestation and we also showed that those associations can last up to 6 years post-delivery. Pregnancy induces physiological changes that uniquely affect maternal metabolism influencing post-partum weight retention.<sup>83,84</sup> Weight gain can be sustained after delivery through weight retention triggered by proinflammatory processes starting during conception.85-87 For instance, during gestation major changes in lipid and glucose homeostasis ensure an adequate supply of energy to the developing fetus.<sup>88,89</sup> These changes could promote body fat accumulation, <sup>90,91</sup> changes in leptin hormone levels, 92 increased glucose production, 93 which in turn, can lead to increased risk of developing gestational diabetes<sup>94</sup> and subsequent type-2 diabetes or cardiovascular diseases later in life. 49,50 Increased adiposity has been previously observed in adults exposed to PM<sub>2.5</sub>. 95-97 PM<sub>2.5</sub> exposures during mid-pregnancy altered cholesterol levels up to the 4-year post-delivery visit. Our findings showed that pregnancy and early post-partum PM<sub>2.5</sub> exposure increased

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

levels of LDL and decreased levels of HDL. These PM<sub>2.5</sub>-associated increases in LDL levels or decreases in HDL levels in women having undergone pregnancy were consistent with previous literature in non-pregnant adults.<sup>28,98</sup> Higher LDL and lower HDL cholesterol levels have been shown to predispose women to higher risk of cardiovascular events later in life.<sup>99-101,102,103</sup> Currently, there is a scarcity of studies examining lipid levels in pregnant women that also examine critical periods of susceptibility to PM<sub>2.5</sub> but one lipidomic study indicated that PM<sub>2.5</sub> during the 2<sup>nd</sup> trimester can exacerbate adverse birth outcomes in women with hyperlipidemia through increased inflammation.<sup>104</sup>

Our findings also suggested that pregnancy PM<sub>2.5</sub> exposures are associated with adiposity and adverse lipid alterations up to 6 years post-delivery but not at 8 years in our sample. It is possible that PM<sub>2.5</sub> exposures during and surrounding pregnancy may still have lingering deleterious effects at later stages in life but subsequent exposures could also be inflicting adverse effects and drown out the signal of more distant exposure such as those occurring in pregnancy years prior. Moreover, future studies with longer follow-up time are needed to elucidate whether protracted effects from pregnancy PM<sub>2.5</sub> exposure go beyond 6 years postdelivery. To evaluate the potential influence of concurrent PM<sub>2.5</sub> exposures, we adjusted for average PM<sub>2.5</sub> exposures throughout a 1-year span prior to each examination visit as a timevarying variable in sensitivity analyses, which did not change the results of primary analyses. Although differences in associations over time may reflect women's lifestyle changes and/or weight changes after giving birth, we controlled for several time-varying lifestyle variables in analyses. In addition, we did not observe clear patterns of associations between lagged PM<sub>2.5</sub> exposures throughout pregnancy and anthropometric markers other than WC, suggesting that protracted PM<sub>2.5</sub> exposures may have later effects on abdominal adiposity but perhaps not on generalized adiposity in birthing people, which is in line with the absence of associations with total body fat in our study.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

We also observed potential diverging effects by fetal sex in our study. Critical windows of susceptibility to pregnancy PM<sub>2.5</sub> exposure may be sex-dimorphic due to different circulating levels of sex-steroid hormones during pregnancy<sup>79,80</sup> that may exacerbate or alter effects from air pollution. Our findings are consistent with previous literature indicating that carrying a male fetus is accompanied with a higher risk of poor cardiovascular health for the mother resulting in pregnancy complications and/or adverse health.<sup>54</sup> Moreover, our results indicated also a suggestive protective role of FA against protracted effects from PM<sub>2.5</sub> exposure. These results are consistent with prior findings in PROGRESS mothers showing beneficial effects of higher FA intake levels (above 600 mcg/day) during pregnancy in the associations of air pollutant mixtures and risk of liver injury.<sup>81</sup> In addition to cardiometabolic outcomes, FA has been shown in prior literature to attenuate the risk of adverse birth outcomes induced by airborne particulate matter during pregnancy. 55 However, these hypotheses suggested in stratified analyses warrant further exploration and need to be formally tested with new methods accommodating for distributed lag models that can handle multiple modifying factors. We also recognize potential limitations in our study. First, estimates for months 7 through 9 after LMP refer to a population at the 3<sup>rd</sup> trimester of gestation but also encompasses a small fraction of women (n=55; ~11%) with early-term pregnancies (baby born before the 37<sup>th</sup> week of pregnancy). Second, our study intended to focus specifically in the most relevant epidemics of generalized and abdominal adiposity in the Mexican population, as well as its top major dyslipidemias: hypoalphalipoproteinemia and hypercholesterolemia. However, other markers of metabolic syndrome such as blood pressure and diabetes-markers may be of interest to explore in future studies. We also acknowledge potential measurement error from self-reported covariates and underreport of compromising lifestyle information during pregnancy such as alcohol intake and smoking. 105,106 While we acknowledge that measurement errors of the

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

exposure modeling can introduce some degree of exposure misclassification, we believe that our overall approach—including the use of validated models, cross-validation, and conservative monthly exposure averaging—reduces these errors and enhances the reliability of the estimates. We also used the first day of the LMP as a proxy for conception, which can be prone to biological error. 107,108 However, we do not expect a substantial change in the interpretation as it was conducted in monthly intervals, thus minimizing the biological error, and we used a validated approach to identify LMP when gestational age differed by more than three weeks to LMP (**Methods S2**). 62 In addition, due to the poor analytical performance of LDL-C analysis methods, 109,110 no direct LDL measurement in blood was performed in our study. Although a comprehensive adjustment of covariates was implemented, unmeasured confounding biasing results could also still be present as this is an observational study. Given that it is an observational study, we recognize that we cannot directly establish a causal relationship between critical windows to PM<sub>2.5</sub> exposure on maternal lipids and waist circumference and that instead we are examining associations. Similarly, we did not measure other concurrent environmental exposures that could be correlated with PM<sub>2.5</sub> driving the associations. Also, our effect estimates are small and results should be interpreted with caution. Last, although this study in Mexican women may not be generalizable to other populations, using a relatively homogenous sample increases the internal validity of our results. Our study also benefits from several strengths. To our knowledge, this is the first study assessing the long-term cardiometabolic effects of pregnancy PM<sub>2.5</sub> exposure in a Hispanic population and using a comprehensive panel of anthropometric and lipids. Our study also uses state-of-the-art methods to characterize daily PM<sub>2.5</sub> air pollution data. We also used a novel application of a recently developed statistical model to simultaneously estimate critical windows of exposure in a trajectory analysis with repeated outcome assessment and a continuous time component. This has the advantage to reduce bias using the DLM framework<sup>111</sup> while pooling

strength and gaining power from repeated outcome assessments. We also leveraged a population of pregnant women from Central Mexico exposed to high PM<sub>2.5</sub> levels that could be more susceptible to developing cardiometabolic diseases. In Mexico, the prevalence of overweight and obesity reached 39% in 2018 with mid-life adults, and women in particular, having the highest rates.<sup>112</sup> Our study also highlights that in Mexico City average PM<sub>2.5</sub> levels are 4-5 times the WHO recommended annual average levels (5 µg/m³), <sup>113</sup> making these findings of interest to help drive policy change, and particularly in view of the UN Sustainable Development Goals aiming to prevent non-communicable diseases in lower-middle-income countries. <sup>114</sup> Additional studies should be conducted in pregnant women with more than eight years of follow-up, using multi-pollutant protracted exposures, directly measuring LDL via centrifugation or homogenous assays, <sup>109,115</sup> leveraging different populations outside Mexico, and evaluating high-order interactions with effect modifiers. Our study provides a framework for assessing windows of susceptibility with trajectory outcomes that can be replicated in such future studies.

### 5. Conclusion

Pregnancy itself may constitute a critical window to PM<sub>2.5</sub> exposure for dysregulated long-term maternal metabolic health after delivery. Pregnant women could largely benefit from policies targeting reduction to air pollution exposure.

#### 6. Data Sharing

Data is only available upon reasonable request from the authors.

7. Funding 363 This project was supported by NIEHS grant R01ES032242 (PI: Colicino, Wu); R01ES034521 364 365 (PI: Colicino, Jusko). 366 8. Acknowledgements 367 368 The work involved in this study was also supported by UL1TR004419 (PI: Wright), 369 P30ES023515 (Pl: Wright), R01ES029943 (Pl: Kioumourtzoglou, Weisskopf), R01ES033688 370 (PI: Valvi), R21ES035148 (PI: Valvi). 371 9. Author Contributions 372 E.C., A.W.: Conceptualization; S.I.A., D.D.: Data curation, Formal analysis, Investigation; E.C., 373 374 H.W., A.A.B.: Funding acquisition; S.I.A., D.D.: Software, Visualization; S.I.A., D.D., E.C., A.W., K.K.: Methodology; S.I.A.: Roles/Writing-original draft; D.D., D.V., A.C.J., I.G.A., G.E., 375

M.M.T.R., R.O.W., A.A.B., H.W., K.P.K., A.W., E.C.: Writing—review & editing.

376

Table 1. Main Participant Characteristics in PROGRESS (n=517) a

Variables	Mean (SD) [Range]; n (%)
<u>Exposure</u>	
Average Pregnancy PM <sub>2.5</sub> (µg/m³) <sup>b</sup>	22.8 (1.5) [15.9, 27.7]
Fixed Covariates	
Age at parturition (years)	28.1 (5.6) [18.0, 44.0]
Pre-pregnancy BMI <sup>c</sup>	26.5 (4.1) [18.4, 43.5]
Obese (BMI≥30)	96 (19%)
Overweight (BMI≥25 & <30)	214 (41%)
Normal (BMI≥18.5 & <25)	205 (40%)
Underweight (BMI<18.5)	2 (0.4%)
AMAI SES Index <sup>d</sup>	()
Lower	272 (53%)
Medium	190 (37%)
Higher	55 (11%)
Passive or Active Smoking during Pregnancy  No Smoking during Pregnancy	324 (63%)
Smoking during Pregnancy  Smoking during Pregnancy	324 (63%) 193 (37%)
Marital Status at Baseline	133 (31 70)
Married or Living With Partner	417 (81%)
Single, Separated or Divorced	100 (19%)
	100 (1370)
Parity at Baseline First Pregnancy	200 (39%)
Second Pregnancy	181 (35%)
Three or More Pregnancies	136 (26%)
Meteorologic Season at Last Menstrual Period	100 (2070)
Dry/Cold	158 (31%)
Dry/Warm	105 (20%)
Rainy	254 (49%)
Time-Varying Covariates	, ,
Cardiometabolic Medications by Year ~4 <sup>e</sup>	
	44 (0.70()
Yes No/Unknown	14 (2.7%) 503 (97.3%)
Cardiometabolic Medications by Year ~6 <sup>e</sup>	303 (37.376)
Yes	20 (3.9%)
No/Unknown	497 (96.1%)
Cardiometabolic Medications by Year ~8 <sup>e</sup>	
Yes	37 (7.2%)
No/Unknown	480 (92.8%)
Alcohol Intake by Year ~4 <sup>f</sup>	
Yes	59 (11%)
No	458 (89%)
Alcohol Intake by Year ~6 <sup>†</sup>	,,,
Yes	53 (10%)
No Alaska Hataka ku Yasa 20 f	464 (90%)
Alcohol Intake by Year ~8 <sup>f</sup>	

Yes	55 (11%)
No	462 (89%)
Multiple Pregnancies by Year ~4 <sup>9</sup>	
Yes	131 (25%)
No	386 (75%)
Multiple Pregnancies by Year ~6 <sup>g</sup>	
Yes	158 (31%)
No	359 (69%)
Multiple Pregnancies by Year ~8 <sup>g</sup>	
Yes	197 (38%)
No	320 (62%)
Follow-Up Month '48' (Visit at Year ~4) h	56.7 (6.5) [48.0, 80.0]
Follow-Up Month '72' (Visit at Year ~6) h	80.0 (6.8) [71.0, 115.0]
Follow-Up Month '96' (Visit at Year ~8) h	115.3 (8.1) [97.0, 142.0]
Effect Modifiers	
Fetal Sex	
Male	267 (52%)
Female	250 (48%)
FA Intake (mcg/day) i	505.3 (248.2) [7.5, 2,600]
<600 mcg/day	97 (22%)
≥600 mcg/day	339 (78%)

 $<sup>^{\</sup>rm a}$  Mean (SD) [Range]; n (%). Data shown has PM<sub>2.5</sub> exposure information available and with at least one measurement of the outcome across follow-up visits.

<sup>&</sup>lt;sup>b</sup> From 2 months before last menstrual period (LMP) to month 22 after LMP.

<sup>&</sup>lt;sup>c</sup> Estimated from self-reported height at recruitment (trimester 2) and the LMP reported weight obtained from a linear mixed-effects model.

<sup>&</sup>lt;sup>d</sup> Household socio-economic status index.

<sup>&</sup>lt;sup>e</sup> Any cardiometabolic medication self-reported cumulatively at month 48 follow-up visit, prior to or at the 72 month follow-up visit, and prior to or at the 96 month follow-up visit, respectively.

<sup>&</sup>lt;sup>f</sup> Any alcohol intake self-reported during pregnancy, at each respective follow-up stage (48, 72, or 96 months), or report of previous alcohol intake (ever drinking) before pregnancy.

<sup>&</sup>lt;sup>9</sup> Self-reported additional pregnancy or pregnancies by each respective follow-up stage (48, 72, or 96 months) after index pregnancy (parturition).

<sup>&</sup>lt;sup>h</sup> Continuous time component included as effect modifier in analyses. Missing participants across visits were n=62 at year ~4, n=51 at year ~6, and n=16 at year ~8.

Average FA intake during pregnancy (average of trimesters 2 and 3). n=81 participants with missing information and not included in stratified analyses.

Table 2. Participant Cardiometabolic Outcomes at each Follow-up Visit <sup>a</sup>

	48 Months (~4 Years) Mean (SD) [Range]	72 Months (~6 Years) Mean (SD) [Range]	96 Months (~8 Years) Mean (SD) [Range]
Anthropometric Measures			
Body Mass Index (BMI in kg/m²)	27.5 (4.9) [16.4, 45.4]	28.0 (5.1) [17.9, 49.6]	29.1 (5.2) [16.1, 53.7]
	n=455	n=426	n=503
Waist Circumference (WC in cm)	94.2 (12.2) [63.6, 133.3]	92.6 (11.9) [61.1, 132.6]	95.3 (13.0) [62.9, 167.6]
	n=440	n=453	n=492
Body Fat (%)	38.1 (6.6) [16.3, 53.9]	38.4 (7.0) [3.0, 54.7]	40.4 (6.2) [19.9, 54.3]
	n=439	n=451	n=493
Cholesterol Levels			
Total Cholesterol (mg/dL)	185.2 (39.5) [98.0, 441.0]	179.8 (32.9) [74.0, 407.0]	179.1 (34.1) [91.0, 322.0]
	n=447	n=462	n=499
High-Density Lipoprotein (HDL in mg/dL)	51.3 (12.1) [29.5, 163.0]	48.6 (11.9) [10.5, 135.4]	47.2 (11.0) [21.0, 93.0]
	n=447	n=462	n=499
Low-Density Lipoprotein (LDL in mg/dL)	108.5 (33.9) [17.3, 308.2]	103.6 (27.9) [22.1, 261.6]	104.7 (29.0) [10.8, 226.5]
	n=447	n=462	n=499

<sup>&</sup>lt;sup>a</sup> Data shown has PM<sub>2.5</sub> exposure information available and was restricted to observations with at least one of the outcomes of interest at each stage.

**Figure 1.** Estimates of the association (blue dots) and 95% confidence interval (95% CI) (grey whiskers) between monthly PM<sub>2.5</sub> exposure and anthropometric measures Body Mass Index (BMI), Waist Circumference (WC), body fat percentage at 48, 72, and 96 months (~4, 6, 8 years) after delivery using distributed lag interaction models (DLIMs) with penalization and non-linear modification. Negative and positive values on the x-axis indicate months before and after last menstrual period (LMP), respectively. Month 0 indicates the LMP month (month 0). Models were adjusted for age, pre-pregnancy BMI, socio-economic status, smoking during pregnancy, marital status, parity at enrollment, meteorological season, cardiometabolic medications, alcohol intake, multiple pregnancies throughout follow-up, stage, and follow-up time in months squared to allow for a non-linear effect. Sample sizes for analyses with BMI were n=516 and sample sizes for analyses with WC and body fat were n=515.

**Figure 2.** Estimates of the association (blue dots) and 95% confidence interval (95% CI) (grey whiskers) between monthly PM<sub>2.5</sub> exposure and total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) at 48, 72, and 96 months (~4, 6, and 8 years) after delivery using distributed lag interaction models (DLIMs) with penalization and non-linear modification. Negative and positive values on the x-axis indicate months before and after last menstrual period (LMP), respectively. Month 0 indicates the LMP month (month 0). Models were adjusted for age, pre-pregnancy BMI, socio-economic status, smoking during pregnancy, marital status, parity at enrollment, meteorological season, cardiometabolic medications, alcohol intake, multiple pregnancies throughout follow-up, stage, and follow-up time in months squared to allow for a non-linear effect. Sample sizes for analyses with total cholesterol, HDL, and LDL were n=517.

#### References

- 1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Sep 10 2019;140(11):e563-e595. doi:10.1161/cir.000000000000077
- 2. Grundy SM, Stone NJ, Bailey AL, et al. 2018
  AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood
  Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association
  Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2019/06/25/2019;73(24):3168-3209. doi:https://doi.org/10.1016/j.jacc.2018.11.002
- 3. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. Dec 22 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
- 4. O'Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. *J Am Coll Cardiol*. Jul 12 2022;80(2):138-151. doi:10.1016/j.jacc.2022.04.046
- 5. Miranda JJ, Barrientos-Gutiérrez T, Corvalan C, et al. Understanding the rise of cardiometabolic diseases in lowand middle-income countries. *Nature Medicine*. 2019/11/01 2019;25(11):1667-1679. doi:10.1038/s41591-019-0644-7
- 6. Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Castro-Porras L, Gómez-Velasco D, Mehta R. Trends in the prevalence of metabolic syndrome and its components in Mexican adults, 2006-2018. *Salud Publica Mex.* Nov 5 2021;63(6, Nov-Dic):713-724. doi:10.21149/12835
- 7. Marquezine GF, Oliveira CM, Pereira AC, Krieger JE, Mill JG. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. *Int J Cardiol.* Sep 26 2008;129(2):259-65. doi:10.1016/j.ijcard.2007.07.097
- 8. Florez H, Silva E, Fernández V, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. *Diabetes Res Clin Pract*. Jul 2005;69(1):63-77. doi:10.1016/j.diabres.2004.11.018
- 9. GBD 2019 Diabetes in the Americas Collaborators. Burden of diabetes and hyperglycaemia in adults in the Americas, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Diabetes Endocrinol*. Sep 2022;10(9):655-667. doi:10.1016/s2213-8587(22)00186-3
- 10. Castro-Porras LV, Rojas-Martínez R, Aguilar-Salinas CA, Bello-Chavolla OY, Becerril-Gutierrez C, Escamilla-Nuñez C. Trends and age-period-cohort effects on hypertension mortality rates from 1998 to 2018 in Mexico. *Sci Rep.* Sep 2 2021;11(1):17553. doi:10.1038/s41598-021-96175-0
- 11. Javed Z, Maqsood MH, Amin Z, Nasir K. Race and Ethnicity and Cardiometabolic Risk Profile: Disparities Across Income and Health Insurance in a National Sample of US Adults. *Journal of Public Health Management and Practice*. 2022;28(Supplement 1):S91-S100. doi:10.1097/phh.000000000001441
- 12. Heiss G, Snyder ML, Teng Y, et al. Prevalence of Metabolic Syndrome Among Hispanics/Latinos of Diverse Background: The Hispanic Community Health Study/Study of Latinos. *Diabetes Care*. 2014;37(8):2391-2399. doi:10.2337/dc13-2505
- 13. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, et al. Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. *Salud Publica Mex.* Mar-Apr 2020;62(2):137-146. Prevalencia de dislipidemias, diagnóstico previo, tratamiento y control: resultados de la Ensanut 2012. doi:10.21149/10520
- 14. Barquera S, Hernández-Barrera L, Trejo-Valdivia B, Shamah T, Campos-Nonato I, Rivera-Dommarco J. Obesity in Mexico, prevalence and trends in adults. Ensanut 2018-19. *salud pública de méxico*. 2020;62(6):682-692.
- 15. Tseng C-Y. Characteristics of Atmospheric PM2.5 in a Densely Populated City with Multi-Emission Sources. *Aerosol and Air Quality Research.* 2016;16(9):2145-2158. doi:10.4209/aagr.2016.06.0269
- 16. Kim KH, Kabir E, Kabir S. A review on the human health impact of airborne particulate matter. *Environ Int*. Jan 2015;74:136-43. doi:10.1016/j.envint.2014.10.005
- 17. Li Z, Tang Y, Song X, Lazar L, Li Z, Zhao J. Impact of ambient PM(2.5) on adverse birth outcome and potential molecular mechanism. *Ecotoxicol Environ Saf.* Mar 2019;169:248-254. doi:10.1016/j.ecoenv.2018.10.109
- 18. Nieuwenhuijsen MJ, Basagaña X, Dadvand P, et al. Air pollution and human fertility rates. *Environ Int*. Sep 2014;70:9-14. doi:10.1016/j.envint.2014.05.005
- 19. Carré J, Gatimel N, Moreau J, Parinaud J, Léandri R. Does air pollution play a role in infertility?: a systematic review. *Environ Health*. Jul 28 2017;16(1):82. doi:10.1186/s12940-017-0291-8

- 20. Saleem A, Awan T, Akhtar MF. A comprehensive review on endocrine toxicity of gaseous components and particulate matter in smog. Review. *Frontiers in Endocrinology*. 2024-January-30 2024;15doi:10.3389/fendo.2024.1294205
- 21. Kim JS, Chen Z, Alderete TL, et al. Associations of air pollution, obesity and cardiometabolic health in young adults: The Meta-AIR study. *Environ Int*. Dec 2019;133(Pt A):105180. doi:10.1016/j.envint.2019.105180
- Furlong MA, Klimentidis YC. Associations of air pollution with obesity and body fat percentage, and modification by polygenic risk score for BMI in the UK Biobank. *Environ Res.* Jun 2020;185:109364. doi:10.1016/j.envres.2020.109364
- 23. Luo H, Zhang Q, Yu K, Meng X, Kan H, Chen R. Long-term exposure to ambient air pollution is a risk factor for trajectory of cardiometabolic multimorbidity: A prospective study in the UK Biobank. *EBioMedicine*. Oct 2022;84:104282. doi:10.1016/j.ebiom.2022.104282
- 24. Xu X, Yavar Z, Verdin M, et al. Effect of early particulate air pollution exposure on obesity in mice: role of p47phox. *Arterioscler Thromb Vasc Biol*. Dec 2010;30(12):2518-27. doi:10.1161/ATVBAHA.110.215350
- Sun Q, Yue P, Deiuliis JA, et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. *Circulation*. Feb 3 2009;119(4):538-46. doi:CIRCULATIONAHA.108.799015 [pii]

#### 10.1161/CIRCULATIONAHA.108.799015

- Wallwork RS, Colicino E, Zhong J, et al. Ambient Fine Particulate Matter, Outdoor Temperature, and Risk of Metabolic Syndrome. *Am J Epidemiol*. Jan 1 2017;185(1):30-39. doi:10.1093/aje/kww157
- 27. Dabass A, Talbott EO, Venkat A, et al. Association of exposure to particulate matter (PM2.5) air pollution and biomarkers of cardiovascular disease risk in adult NHANES participants (2001-2008). *Int J Hyg Environ Health*. May 2016;219(3):301-10. doi:10.1016/j.ijheh.2015.12.002
- 28. Yitshak Sade M, Kloog I, Liberty IF, Schwartz J, Novack V. The Association Between Air Pollution Exposure and Glucose and Lipids Levels. *J Clin Endocrinol Metab*. Jun 2016;101(6):2460-7. doi:10.1210/jc.2016-1378
- 29. Tamayo-Ortiz M, Téllez-Rojo MM, Rothenberg SJ, et al. Exposure to PM2.5 and Obesity Prevalence in the Greater Mexico City Area. *International Journal of Environmental Research and Public Health*. 2021;18(5):2301.
- 30. Colicino E, Ferrari F, Cowell W, et al. Non-linear and non-additive associations between the pregnancy metabolome and birthweight. *Environment International*. 2021/11/01/ 2021;156:106750. doi:https://doi.org/10.1016/j.envint.2021.106750
- 31. Colicino E, Cowell W, Foppa Pedretti N, et al. Maternal steroids during pregnancy and their associations with ambient air pollution and temperature during preconception and early gestational periods. *Environment International*. 2022/07/01/2022;165:107320. doi:https://doi.org/10.1016/j.envint.2022.107320
- 32. Gangwar RS, Bevan GH, Palanivel R, Das L, Rajagopalan S. Oxidative stress pathways of air pollution mediated toxicity: Recent insights. *Redox Biol.* Jul 2020;34:101545. doi:10.1016/j.redox.2020.101545
- Rao X, Zhong J, Brook RD, Rajagopalan S. Effect of Particulate Matter Air Pollution on Cardiovascular Oxidative Stress Pathways. *Antioxid Redox Signal*. Mar 20 2018;28(9):797-818. doi:10.1089/ars.2017.7394
- Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. *Vascul Pharmacol.* Jan 2018;100:1-19. doi:10.1016/j.vph.2017.05.005
- 35. Sun M, Yan W, Fang K, et al. The correlation between PM(2.5) exposure and hypertensive disorders in pregnancy: A Meta-analysis. *Sci Total Environ*. Feb 10 2020;703:134985. doi:10.1016/j.scitotenv.2019.134985
- 36. Hu H, Ha S, Xu X. Ozone and hypertensive disorders of pregnancy in Florida: Identifying critical windows of exposure. *Environ Res.* Feb 2017;153:120-125. doi:10.1016/j.envres.2016.12.002
- 37. Lu C, Zhang W, Zheng X, Sun J, Chen L, Deng Q. Combined effects of ambient air pollution and home environmental factors on low birth weight. *Chemosphere*. Feb 2020;240:124836. doi:10.1016/j.chemosphere.2019.124836
- 38. Chen Q, Ren Z, Liu Y, et al. The Association between Preterm Birth and Ambient Air Pollution Exposure in Shiyan, China, 2015-2017. *Int J Environ Res Public Health*. Apr 19 2021;18(8)doi:10.3390/ijerph18084326
- 39. Patterson WB, Glasson J, Naik N, et al. Prenatal exposure to ambient air pollutants and early infant growth and adiposity in the Southern California Mother's Milk Study. *Environ Health*. Jun 5 2021;20(1):67. doi:10.1186/s12940-021-00753-8
- 40. McGuinn LA, Bellinger DC, Colicino E, et al. Prenatal PM(2.5) exposure and behavioral development in children from Mexico City. *Neurotoxicology*. Dec 2020;81:109-115. doi:10.1016/j.neuro.2020.09.036

- 41. Warin M, Moore V, Zivkovic T, Davies M. Telescoping the origins of obesity to women's bodies: how gender inequalities are being squeezed out of Barker's hypothesis. *Annals of human biology*. Jul 2011;38(4):453-60. doi:10.3109/03014460.2011.591829
- Varshavsky J, Smith A, Wang A, et al. Heightened susceptibility: A review of how pregnancy and chemical exposures influence maternal health. *Reprod Toxicol*. Mar 2020;92:14-56. doi:10.1016/j.reprotox.2019.04.004
- 43. Kalagiri RR, Carder T, Choudhury S, et al. Inflammation in Complicated Pregnancy and Its Outcome. *Am J Perinatol*. Dec 2016;33(14):1337-1356. doi:10.1055/s-0036-1582397
- 44. Kamity R, Sharma S, Hanna N. MicroRNA-Mediated Control of Inflammation and Tolerance in Pregnancy. *Front Immunol*. 2019;10:718. doi:10.3389/fimmu.2019.00718
- 45. Tenório MB, Ferreira RC, Moura FA, Bueno NB, de Oliveira ACM, Goulart MOF. Cross-Talk between Oxidative Stress and Inflammation in Preeclampsia. *Oxid Med Cell Longev*. 2019;2019:8238727. doi:10.1155/2019/8238727
- Dalfra MG, Burlina S, Lapolla A. Weight gain during pregnancy: A narrative review on the recent evidences. *Diabetes Res Clin Pract*. Jun 2022;188:109913. doi:10.1016/j.diabres.2022.109913
- 47. Wang LJ, Fan DZ, Guo HX, Chen BS, Liu ZP. Weight gain during pregnancy and placenta morphology: a prospective cohort study. *Eur Rev Med Pharmacol Sci.* Mar 2022;26(6):1978-1983. doi:10.26355/eurrev\_202203\_28346
- 48. Committee to Reexamine IOM Pregnancy Weight Guidelines, ed. *Weight Gain During Pregnancy: Reexamining the Guidelines*. Institute of Medicine and National Research Council; 2009. Rasmussen KM, Yaktine AL, eds.
- 49. Rich-Edwards JW, McElrath TF, Karumanchi SA, Seely EW. Breathing life into the lifecourse approach: pregnancy history and cardiovascular disease in women. *Hypertension*. Sep 2010;56(3):331-4. doi:10.1161/HYPERTENSIONAHA.110.156810
- 50. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. *JAMA*. Dec 7 2005;294(21):2751-7. doi:10.1001/jama.294.21.2751
- 51. Lee KK, E AR, Lee AJ, et al. 115 Maternal Obesity during Pregnancy and Premature Cardiovascular Mortality in Later Life. *Heart*. Jun 2014;100 Suppl 3:A65-6. doi:10.1136/heartjnl-2014-306118.115
- Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: A systematic review. *The Journal of clinical psychiatry*. Aug 2006;67(8):1285-98.
- 53. Demateis D, Keller KP, Rojas-Rueda D, Kioumourtzoglou M-A, Wilson A. Penalized distributed lag interaction model: Air pollution, birth weight, and neighborhood vulnerability. *Environmetrics*. 2024;35(4):e2843. doi:https://doi.org/10.1002/env.2843
- Broere-Brown ZA, Adank MC, Benschop L, et al. Fetal sex and maternal pregnancy outcomes: a systematic review and meta-analysis. *Biology of Sex Differences*. 2020/05/11 2020;11(1):26. doi:10.1186/s13293-020-00299-3
- 55. Li Q, Wang Y-Y, Guo Y, et al. Folic Acid Supplementation and the Association between Maternal Airborne Particulate Matter Exposure and Preterm Delivery: A National Birth Cohort Study in China. *Environmental Health Perspectives*. 2020;128(12):127010. doi:doi:10.1289/EHP6386
- 56. Braun JM, Wright RJ, Just AC, et al. Relationships between lead biomarkers and diurnal salivary cortisol indices in pregnant women from Mexico City: a cross-sectional study. *Environ Health*. Jun 10 2014;13(1):50. doi:10.1186/1476-069x-13-50
- 57. Gutiérrez-Avila I, Arfer KB, Carrión D, et al. Prediction of daily mean and one-hour maximum PM2.5 concentrations and applications in Central Mexico using satellite-based machine-learning models. *Journal of Exposure Science & Environmental Epidemiology*. 2022/09/10 2022;doi:10.1038/s41370-022-00471-4
- 58. Soria-Contreras DC, Trejo-Valdivia B, Cantoral A, et al. Patterns of Weight Change One Year after Delivery Are Associated with Cardiometabolic Risk Factors at Six Years Postpartum in Mexican Women. *Nutrients*. Jan 7 2020;12(1)doi:10.3390/nu12010170
- 59. Centers for Disease Control and Prevention NCfHS. NHANES 2019-2020 Procedure Manuals. 2024. <a href="https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2019">https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2019</a>
- 60. Ostchega Y SR, Sarafrazi Isfahani N, Zhang G, Hughes JP, Miller I. . Waist circumference measurement methodology study: National Health and Nutrition Examination Survey, 2016. Centers for Disease Control and Prevention, National Center for Health Statistics. Vital Health Stat. 2024.

https://www.cdc.gov/nchs/data/series/sr 02/sr02 182-508.pdf

- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* Jun 1972;18(6):499-502.
- 62. Capurro H, Konichezky S, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosis of gestational age in the newborn infant. *The Journal of Pediatrics*. 1978;93(1):120-122. doi:10.1016/S0022-3476(78)80621-0

- Thomas DM, Oken E, Rifas-Shiman SL, et al. Do Women Know Their Prepregnancy Weight? *Obesity*. 2019;27(7):1161-1167. doi:https://doi.org/10.1002/oby.22502
- 64. AV C. The AMAI system of classifying households by socio-economic level: ESOMAR. 2002;
- 65. Bartz-Beielstein SMaT. imputeTS: Time Series Missing Value Imputation in R. *The R Journal*. 2017;9(1):207-218. doi:10.32614/RJ-2017-009
- 66. Schummers L, Hutcheon JA, Hacker MR, et al. Absolute risks of obstetric outcomes by maternal age at first birth: a population-based cohort. *Epidemiology*. May 2018;29(3):379-387. doi:10.1097/ede.0000000000000818
- Wang X, Karvonen-Gutierrez CA, Gold EB, et al. Longitudinal Associations of Air Pollution With Body Size and Composition in Midlife Women: The Study of Women's Health Across the Nation. *Diabetes Care*. Nov 1 2022;45(11):2577-2584. doi:10.2337/dc22-0963
- 68. Chi GC, Hajat A, Bird CE, et al. Individual and Neighborhood Socioeconomic Status and the Association between Air Pollution and Cardiovascular Disease. *Environ Health Perspect*. Dec 2016;124(12):1840-1847. doi:10.1289/ehp199
- 69. Patel K, Hargreaves MK, Liu J, et al. Relationship between smoking and obesity among women. *Am J Health Behav*. Sep 2011;35(5):627-36. doi:10.5993/ajhb.35.5.11
- 70. Fu M, Martínez-Sánchez JM, Galán I, et al. Variability in the correlation between nicotine and PM2.5 as airborne markers of second-hand smoke exposure. *Environ Res.* Nov 2013;127:49-55. doi:10.1016/j.envres.2013.09.003
- 71. Wickrama KAS, O'Neal CW, Neppl TK. Midlife Family Economic Hardship and Later Life Cardiometabolic Health: The Protective Role of Marital Integration. *Gerontologist*. Sep 17 2019;59(5):892-901. doi:10.1093/geront/gny047
- 72. Stokes JE, Barooah A. Dyadic Loneliness and Changes to HbA1c Among Older US Couples: The Role of Marital Support as Stress Buffer. *J Aging Health*. Oct 2021;33(9):698-708. doi:10.1177/08982643211006498
- Li W, Ruan W, Lu Z, Wang D. Parity and risk of maternal cardiovascular disease: A dose–response meta-analysis of cohort studies. *European Journal of Preventive Cardiology*. 2020;26(6):592-602. doi:10.1177/2047487318818265
- 74. Mahalingaiah S, Hart JE, Laden F, et al. Adult air pollution exposure and risk of infertility in the Nurses' Health Study II. *Hum Reprod.* Mar 2016;31(3):638-47. doi:10.1093/humrep/dev330
- 75. Zhang L, An J, Liu M, et al. Spatiotemporal variations and influencing factors of PM(2.5) concentrations in Beijing, China. *Environ Pollut*. Jul 2020;262:114276. doi:10.1016/j.envpol.2020.114276
- 76. Blauw LL, Aziz NA, Tannemaat MR, et al. Diabetes incidence and glucose intolerance prevalence increase with higher outdoor temperature. *BMJ Open Diabetes Res Care*. 2017;5(1):e000317. doi:10.1136/bmjdrc-2016-000317
- 77. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. *Nutrition, Metabolism and Cardiovascular Diseases*. 2017;27(8):657-669. doi:10.1016/j.numecd.2017.04.009
- 78. Molenaar EA, Massaro JM, Jacques PF, et al. Association of lifestyle factors with abdominal subcutaneous and visceral adiposity: the Framingham Heart Study. *Diabetes Care*. Mar 2009;32(3):505-10. doi:10.2337/dc08-1382
- 79. Clifton VL. Review: Sex and the Human Placenta: Mediating Differential Strategies of Fetal Growth and Survival. *Placenta*. 2010/03/01/2010;31:S33-S39. doi:https://doi.org/10.1016/j.placenta.2009.11.010
- 80. Morisset A-S, Dubé M-C, Drolet R, et al. Androgens in the maternal and fetal circulation: association with insulin resistance. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2013/03/01 2013;26(5):513-519. doi:10.3109/14767058.2012.735725
- 81. India-Aldana S, Midya V, Betanzos-Robledo L, et al. Metabolism-Disrupting Chemical Mixtures during Pregnancy, Folic Acid Supplementation, and Liver Injury in Mother-Child Pairs. *medRxiv*. 2024:2024.06.13.24308903. doi:10.1101/2024.06.13.24308903
- 82. National Institutes of Health Office of Dietary Supplements. Folate. 2024. <a href="https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/">https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/</a>
- 83. Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. *Nature Reviews Cardiology*. 2020/11/01 2020;17(11):718-731. doi:10.1038/s41569-020-0390-z
- Rong K, Yu K, Han X, et al. Pre-pregnancy BMI, gestational weight gain and postpartum weight retention: a meta-analysis of observational studies. *Public Health Nutr.* Aug 2015;18(12):2172-82. doi:10.1017/s1368980014002523
- 85. Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. *Obesity (Silver Spring)*. Mar 2011;19(3):476-82. doi:10.1038/oby.2010.215
- 86. Egger G, Dixon J. Should obesity be the main game? Or do we need an environmental makeover to combat the inflammatory and chronic disease epidemics? *Obes Rev.* Mar 2009;10(2):237-49. doi:10.1111/j.1467-789X.2008.00542.x

- 87. Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. *Nutrients*. Sep 23 2013;5(9):3757-78. doi:10.3390/nu5093757
- 88. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. *The American Journal of Clinical Nutrition*. 2000;71(5):1256S-1261S. doi:10.1093/ajcn/71.5.1256s
- 89. Grimes SB, Wild R. Effect of Pregnancy on Lipid Metabolism and Lipoprotein Levels. In: Feingold KR, Anawalt B, Boyce A, et al, eds. *Endotext*. MDText.com, Inc.

Copyright © 2000-2022, MDText.com, Inc.; 2000.

- 90. Bosaeus M, Andersson-Hall U, Andersson L, Karlsson T, Ellegård L, Holmäng A. Body Composition During Pregnancy: Longitudinal Changes and Method Comparisons. *Reprod Sci.* Jul 2020;27(7):1477-1489. doi:10.1007/s43032-020-00141-6
- 91. To WW, Wong MW. Body fat composition and weight changes during pregnancy and 6-8 months post-partum in primiparous and multiparous women. *Aust N Z J Obstet Gynaecol*. Feb 2009;49(1):34-8. doi:10.1111/j.1479-828X.2008.00933.x
- 92. Sattar N, Greer IA, Pirwani I, Gibson J, Wallace AM. Leptin levels in pregnancy: marker for fat accumulation and mobilization? *Acta Obstet Gynecol Scand*. Mar 1998;77(3):278-83.
- 93. Bochkur Dratver MA, Arenas J, Thaweethai T, et al. Longitudinal changes in glucose during pregnancy in women with gestational diabetes risk factors. *Diabetologia*. Mar 2022;65(3):541-551. doi:10.1007/s00125-021-05622-0
- 94. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. *Diabetes/metabolism research and reviews*. Jul-Aug 2003;19(4):259-70. doi:10.1002/dmrr.390
- 95. Bowe B, Gibson AK, Xie Y, et al. Ambient Fine Particulate Matter Air Pollution and Risk of Weight Gain and Obesity in United States Veterans: An Observational Cohort Study. *Environ Health Perspect*. Apr 2021;129(4):47003. doi:10.1289/ehp7944
- 26. Zhang N, Wang L, Zhang M, Nazroo J. Air quality and obesity at older ages in China: The role of duration, severity and pollutants. *PLoS One*. 2019;14(12):e0226279. doi:10.1371/journal.pone.0226279
- 97. Li X, Wang M, Song Y, et al. Obesity and the relation between joint exposure to ambient air pollutants and incident type 2 diabetes: A cohort study in UK Biobank. *PLoS Med.* Aug 2021;18(8):e1003767. doi:10.1371/journal.pmed.1003767
- 98. Yeatts K, Svendsen E, Creason J, et al. Coarse particulate matter (PM2.5-10) affects heart rate variability, blood lipids, and circulating eosinophils in adults with asthma. *Environ Health Perspect*. May 2007;115(5):709-14. doi:10.1289/ehp.9499
- 99. Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. *J Am Heart Assoc.* Mar 13 2014;3(2):e000519. doi:10.1161/jaha.113.000519
- 100. Bittner V. Lipoprotein abnormalities related to women's health. *Am J Cardiol*. Oct 17 2002;90(8a):77i-84i. doi:10.1016/s0002-9149(02)02637-1
- 101. Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. *J Am Heart Assoc*. Apr 6 2021;10(7):e016947. doi:10.1161/jaha.120.016947
- 102. Duncan MS, Vasan RS, Xanthakis V. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years. *J Am Heart Assoc*. Jun 4 2019;8(11):e011433. doi:10.1161/jaha.118.011433
- 103. Fernandez ML, Jones JJ, Ackerman D, et al. Low HDL cholesterol is associated with increased atherogenic lipoproteins and insulin resistance in women classified with metabolic syndrome. *Nutr Res Pract.* Dec 2010;4(6):492-8. doi:10.4162/nrp.2010.4.6.492
- Thang J, Chen G, Liang S, et al. PM(2.5) exposure exaggerates the risk of adverse birth outcomes in pregnant women with pre-existing hyperlipidemia: Modulation role of adipokines and lipidome. *Sci Total Environ*. Sep 15 2021;787:147604. doi:10.1016/j.scitotenv.2021.147604
- 105. Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in pregnancy. *Alcohol Clin Exp Res.* Aug 1988;12(4):506-11. doi:10.1111/j.1530-0277.1988.tb00233.x
- 106. Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. *Bmj*. Oct 29 2009;339:b4347. doi:10.1136/bmj.b4347

- 107. Nakling J, Buhaug H, Backe B. The biologic error in gestational length related to the use of the first day of last menstrual period as a proxy for the start of pregnancy. *Early Hum Dev.* Oct 2005;81(10):833-9. doi:10.1016/j.earlhumdev.2005.06.004
- 108. Baskett TF, Nagele F. Naegele's rule: a reappraisal. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2000;107(11):1433-1435. doi:https://doi.org/10.1111/j.1471-0528.2000.tb11661.x
- 109. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clin Chem.* Jun 2010;56(6):977-86. doi:10.1373/clinchem.2009.142810
- 110. Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. *Clin Chem.* Jul 2018;64(7):1006-1033. doi:10.1373/clinchem.2018.287037
- 111. Wilson A, Chiu Y-HM, Hsu H-HL, Wright RO, Wright RJ, Coull BA. Potential for Bias When Estimating Critical Windows for Air Pollution in Children's Health. *American Journal of Epidemiology*. 2017;186(11):1281-1289. doi:10.1093/aje/kwx184
- 112. Barquera S, Hernández-Barrera L, Trejo-Valdivia B, Shamah T, Campos-Nonato I, Rivera-Dommarco J. [Obesity in Mexico, prevalence and rends in adults. Ensanut 2018-19.]. *Salud Publica Mex.* Nov-Dec 2020;62(6):682-692. Obesidad en México, prevalencia y tendencias en adultos. Ensanut 2018-19. doi:10.21149/11630
- 113. World Health Organization (WHO). What are the WHO Air quality guidelines? Accessed 5/22/2023, https://www.who.int/news-room/feature-stories/detail/what-are-the-who-air-quality-guidelines
- 114. Nugent R, Bertram MY, Jan S, et al. Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals. *Lancet*. May 19 2018;391(10134):2029-2035. doi:10.1016/s0140-6736(18)30667-6
- Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. *Clin Chem*. Feb 2002;48(2):236-54.



